<DOC>
	<DOCNO>NCT00566371</DOCNO>
	<brief_summary>This study single site , double-blind , randomize , placebo-controlled parallel group design . study design directly examine efficacy single daily dose atomoxetine take morning alleviate sleep initiation insomnia child ADHD . Primary outcome measure sleep parameter , specifically mean sleep onset latency ( time onset persistent sleep ) , measure actigraphy/sleep diary , parent child-reported evening settling difficulty , measure even subscale item parent child version DPREMB-R . Secondary outcome measure include : additional actigraphic sleep parameter ( night waking , sleep duration , sleep efficiency ) , daytime sleepiness ( Pediatric Daytime Sleepiness Scale , sleepiness visual analogue scale ( VAS ) , morning behavior DPREMB-R ) ; ADHD symptom improvement ( ADHD-RS , parent version ; provider-completed CGI ) ; neurocognitive measure attention impulsivity ( CPT ) ; executive function ( Brown ADD Scale Children ) functional outcomes/quality life ( CHQ ) .</brief_summary>
	<brief_title>The Effect Once Daily Dose Atomoxetine ( ATX ) ADHD-Related Insomnia Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Atomoxetine Hydrochloride</mesh_term>
	<criteria>Subjects child age 6 17 year DSMIV criteriadefined ADHD sleep initiation insomnia . sleep onset delay must exclusively related direct rebound effect psychostimulant treatment . All subject screen primary sleep disorder survey questionnaire ( Children 's Sleep Habits Questionnaire , CSHQ ( 12 ) Restless Sleep Questionnaire ) ( Visit 1 ) ; subject score predefined threshold OSA and/or RLS/PLMD symptom exclude study . Other exclusion criterion include IQ &lt; 80 ( WISCIII screen baseline ) , history significant chronic medical illness ( diabetes , severe asthma ) , comorbid depression significant psychiatric comorbidities ( ODD , LD exclude ; determine screen Diagnostic Interview Schedule Children ( DISC ) ) , history chronic use sedating ( eg , antihistamine ) alertnessenhancing ( eg , caffeine ) medication , history condition use atomoxetine contraindicate ( eg , narrow angle glaucoma ) , use prescription medication ADHD and/or use prescription/OTC medication sleep ( eg , alpha agonist , hypnotic , melatonin , antihistamine ) follow screen visit , history failure respond adequate ( defined appropriate dose adequate duration therapy ) previous trial atomoxetine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2007</verification_date>
	<keyword>attention deficit hyperactivity disorder</keyword>
	<keyword>insomnia</keyword>
	<keyword>atomoxetine</keyword>
</DOC>